| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sadaf Riaz, Islam Ullah Khan, Marek Bajda, Muhammad Ashraf, Qurat-Ul-Ain, Ayesha Shaukat, Tanzeel Ur Rehman, Sadaf Mutahir, Sajjad Hussain, Ghulam Mustafa, Muhammad Ya. Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase. Bioorganic chemistry. vol 63. 2016-09-08. PMID:26451651. |
pyridine sulfonamide as a small key organic molecule for the potential treatment of type-ii diabetes mellitus and alzheimer's disease: in vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase. |
2016-09-08 |
2023-08-13 |
Not clear |
| Kosuke Higashino, Yukio Ago, Takahiro Umeki, Shigeru Hasebe, Yusuke Onaka, Hitoshi Hashimoto, Kazuhiro Takuma, Toshio Matsud. Rivastigmine improves isolation rearing-induced prepulse inhibition deficits via muscarinic acetylcholine receptors in mice. Psychopharmacology. vol 233. issue 3. 2016-08-29. PMID:26518025. |
the acetylcholinesterase inhibitors donepezil, galantamine, and rivastigmine are used for the treatment of alzheimer's disease. |
2016-08-29 |
2023-08-13 |
mouse |
| I Ayelen Ramallo, Mario O Salazar, Ricardo L E Furla. Thin Layer Chromatography-Autography-High Resolution Mass Spectrometry Analysis: Accelerating the Identification of Acetylcholinesterase Inhibitors. Phytochemical analysis : PCA. vol 26. issue 6. 2016-08-22. PMID:26102595. |
the prevailing treatment for alzheimer's disease is the use of acetylcholinesterase (ache) inhibitors. |
2016-08-22 |
2023-08-13 |
Not clear |
| Ruth Lamb, Jonathan D Rohrer, Andrew J Lees, Huw R Morri. Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Current treatment options in neurology. vol 18. issue 9. 2016-08-16. PMID:27526039. |
pharmacological agents licensed for alzheimer's disease (such as acetylcholinesterase inhibitors and n-methyl-d-aspartate receptor antagonists) have been used off-label in psp, cbd, and other tauopathies with the aim of improving cognition; however, there is limited evidence that they are effective and risk of adverse effects may outweigh benefits. |
2016-08-16 |
2023-08-13 |
Not clear |
| Yo Han Kim, Hee Youn Choi, Hyeong-Seok Lim, Shi Hyang Lee, Hae Sun Jeon, Donghyun Hong, Seong Su Kim, Young Kweon Choi, Kyun-Seop Ba. Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug design, development and therapy. vol 9. 2016-08-09. PMID:25792802. |
donepezil is an acetylcholinesterase inhibitor indicated for alzheimer's disease. |
2016-08-09 |
2023-08-13 |
human |
| Catherine Saint-Laurent Thibault, Ipek Özer Stillman, Stephanie Chen, Denis Getsios, Irina Proskorovsky, Luis Hernandez, Shailja Dixi. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. Journal of medical economics. vol 18. issue 11. 2016-08-08. PMID:26086535. |
this study evaluates the cost-effectiveness of memantine extended release (er) as an add-on therapy to acetylcholinesterase inhibitor (achei) [combination therapy] for treatment of patients with moderate-to-severe alzheimer's disease (ad) from both a healthcare payer and a societal perspective over 3 years when compared to achei monotherapy in the us. |
2016-08-08 |
2023-08-13 |
Not clear |
| Ciro Manzo, Salvatore Putignan. Drug-induced lupus erythematosus associated with donepezil: a case report. Age and ageing. vol 44. issue 6. 2016-08-04. PMID:26420637. |
donepezil is an inhibitor of acetylcholinesterase used for the treatment of alzheimer's disease. |
2016-08-04 |
2023-08-13 |
Not clear |
| Robert A Lenz, Yili L Pritchett, Scott M Berry, Daniel A Llano, Shu Han, Donald A Berry, Carl H Sadowsky, Walid M Abi-Saab, Mario D Saltarell. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer disease and associated disorders. vol 29. issue 3. 2016-08-02. PMID:25973909. |
abt-089, an α4β2 neuronal nicotinic receptor partial agonist, was evaluated for efficacy and safety in mild to moderate alzheimer disease patients receiving stable doses of acetylcholinesterase inhibitors. |
2016-08-02 |
2023-08-13 |
Not clear |
| Robert A Lenz, Yili L Pritchett, Scott M Berry, Daniel A Llano, Shu Han, Donald A Berry, Carl H Sadowsky, Walid M Abi-Saab, Mario D Saltarell. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer disease and associated disorders. vol 29. issue 3. 2016-08-02. PMID:25973909. |
when administered as adjunctive therapy to acetylcholinesterase inhibitors, abt-089 was not efficacious in mild to moderate alzheimer disease. |
2016-08-02 |
2023-08-13 |
Not clear |
| Abdul Hameed, Syeda T Zehra, Syed J A Shah, Khalid M Khan, Rima D Alharthy, Norbert Furtmann, Jürgen Bajorath, Muhammad N Tahir, Jamshed Iqba. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives. Chemical biology & drug design. vol 86. issue 5. 2016-08-01. PMID:25951978. |
cholinesterases, acetylcholinesterase (ache) and butyrylcholinesterase (bche), have a role in cholinergic deficit which evidently leads to alzheimer's disease (ad). |
2016-08-01 |
2023-08-13 |
Not clear |
| Teng Chen, Ruihua Hou, Shujun Xu, Chengyuan W. Donepezil Regulates 1-Methyl-4-phenylpyridinium-Induced Microglial Polarization in Parkinson's Disease. ACS chemical neuroscience. vol 6. issue 10. 2016-08-01. PMID:26114860. |
donepezil is a well-known acetylcholinesterase inhibitor used clinically to treat cognitive dysfunction in alzheimer's disease (ad). |
2016-08-01 |
2023-08-13 |
Not clear |
| Mullah Muhaiminul Islam, Arun Bahadur Gurung, Atanu Bhattacharjee, Kripamoy Aguan, Sivaprasad Mitr. Human serum albumin reduces the potency of acetylcholinesterase inhibitor based drugs for Alzheimer's disease. Chemico-biological interactions. vol 249. 2016-08-01. PMID:26902639. |
human serum albumin reduces the potency of acetylcholinesterase inhibitor based drugs for alzheimer's disease. |
2016-08-01 |
2023-08-13 |
human |
| Yao Chen, Yaoyao Bian, Yuan Sun, Chen Kang, Sheng Yu, Tingming Fu, Wei Li, Yuqiong Pei, Haopeng Su. Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. PeerJ. vol 4. 2016-07-21. PMID:27441112. |
inhibition of acetylcholinesterase (ache) using small molecules is still one of the most successful therapeutic strategies in the treatment of alzheimer's disease (ad). |
2016-07-21 |
2023-08-13 |
Not clear |
| Tsuyoshi Sato, Yuichiro Enoki, Yasushi Sakamoto, Kazuhiro Yokota, Masahiko Okubo, Masahito Matsumoto, Naoki Hayashi, Michihiko Usui, Shoichiro Kokabu, Toshihide Mimura, Yoshihiko Nakazato, Nobuo Araki, Toru Fukuda, Yasushi Okazaki, Tatsuo Suda, Shu Takeda, Tetsuya Yod. Donepezil prevents RANK-induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase. Heliyon. vol 1. issue 1. 2016-07-21. PMID:27441211. |
donepezil, an inhibitor of acetylcholinesterase (ache) targeting the brain, is a common medication for alzheimer's disease. |
2016-07-21 |
2023-08-13 |
Not clear |
| Yong Li, Xiao-Xiao Zhang, Li-Juan Jiang, Li Yuan, Ting-Ting Cao, Xia Li, Lin Dong, Ying Li, Shu-Fan Yi. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease. Chemical biology & drug design. vol 86. issue 4. 2016-07-20. PMID:25736722. |
inhibition of acetylcholinesterase (ache): a potential therapeutic target to treat alzheimer's disease. |
2016-07-20 |
2023-08-13 |
Not clear |
| An Zhou, Jianping Hu, Lirong Wang, Guochen Zhong, Jian Pan, Zeyu Wu, Ailing Hu. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease. Journal of molecular modeling. vol 21. issue 10. 2016-07-11. PMID:26438408. |
combined 3d-qsar, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (ache) inhibitors of alzheimer's disease. |
2016-07-11 |
2023-08-13 |
Not clear |
| An Zhou, Jianping Hu, Lirong Wang, Guochen Zhong, Jian Pan, Zeyu Wu, Ailing Hu. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease. Journal of molecular modeling. vol 21. issue 10. 2016-07-11. PMID:26438408. |
acetylcholinesterase (ache) is one of the key targets of drugs for treating alzheimer's disease (ad). |
2016-07-11 |
2023-08-13 |
Not clear |
| Justin Tao Wen Chiam, Katie Lunnon, Nicola Voyle, Petroula Proitsi, Giovanni Coppola, Daniel Geschwind, Sally Nelson, Caroline Johnston, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Angela Hodges, Simon Lovestone, Stephen Newhouse, Richard James Butler Dobson, Steven John Kiddle, Martina Sattlecke. No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's disease : JAD. vol 47. issue 3. 2016-07-06. PMID:26401708. |
no evidence to suggest that the use of acetylcholinesterase inhibitors confounds the results of two blood-based biomarker studies in alzheimer's disease. |
2016-07-06 |
2023-08-13 |
Not clear |
| Hao-Ran Liu, Chao Zhou, Hao-Qun Fan, Jing-Jing Tang, Lin-Bo Liu, Xiao-Hui Gao, Qiu-An Wang, Wu-Kun Li. Novel Potent and Selective Acetylcholinesterase Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease: Synthesis, Pharmacological Evaluation, and Molecular Modeling of Amino-Alkyl-Substituted Fluoro-Chalcones Derivatives. Chemical biology & drug design. vol 86. issue 4. 2016-07-04. PMID:25588967. |
novel potent and selective acetylcholinesterase inhibitors as potential drugs for the treatment of alzheimer's disease: synthesis, pharmacological evaluation, and molecular modeling of amino-alkyl-substituted fluoro-chalcones derivatives. |
2016-07-04 |
2023-08-13 |
Not clear |
| H Shimada, S Hirano, H Sinotoh, T Ota, N Tanaka, K Sato, M Yamada, K Fukushi, T Irie, M R Zhang, M Higuchi, S Kuwabara, T Suhar. Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study. International journal of geriatric psychiatry. vol 30. issue 11. 2016-07-01. PMID:26280153. |
dementia with lewy bodies can be well-differentiated from alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11c]mp4a pet study. |
2016-07-01 |
2023-08-13 |
Not clear |